2Mulloy LL,Wright F,Hall ML,et al.Basiliximab reduces acute cellular rejection in renal allografts from cadaveric and living donors.Transplant Proc,1999,31:1210-1213.
3Naie MP,Nampoery MR,Johny KV,et al.Iuduction immunosuppression with interleukin-2 receptor antibodies (basiliximab and daclizumab) in renal transplant recipients.Transplant Proc,2001,33:2767-2769.
4Kahan BD,Rajagopalan PR,Hall M.Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab,a chimeric anti-interleukin-2-receptor monoclonal antibody.United States Basiliximab Renal Study Group.Transpl
5Nashan B,Light S,Hardie IR,et al.Reduction of acute renal allograft rejection by daclizumab.Transplantation,1999,67:110-113.
6Ponticelli C,Yussim A,Cambi V,et al.Basiliximab significantly reduces acute rejection in renal transplant patients given triple therapy with azathioprine.Transplant Proc,2001,33:1009-1010.
8Kovark J,Wolf P,Cisterne JM,et al.Disposition of basiliximab,an interleukin-2 receptor monoclonal antibody,in recipients of mismatched cadaver renal allografts.Transplantation,1997,64:1701-1705.
9Hakimi J,Ha VC,Lin P,et al.Humanized Mik 1,a humanized antibody to the IL-2 receptor-chain that acts synergistically with humanized anti-TAG.J Immunol,1993,151:1075-1077.
10Ekberg H,Backman L,Tufveson G,et al.Daclizumab reduces the incidence of acute rejection episodes and improve patient survival following renal transplantation.Transplant Proc,1999,31:267-268.
